HomeMedication lookupDrug classes › Chemotherapy agents
Chemotherapy

Chemotherapy agents and pharmacogenetics

Also known as: Cancer medications, Oncology drugs

12 medications 17 brand products DPYDTPMTUGT1A1

Why pharmacogenetics matter for chemotherapy agents

Pharmacogenetic testing in oncology is the most well-established and consequential part of clinical pharmacogenetics. Several chemotherapy drugs have mandatory or strongly recommended pre-treatment genetic testing because the toxicity difference between a normal metabolizer and a deficient metabolizer can be the difference between a typical treatment course and severe, sometimes fatal, toxicity.

DPYD testing before fluoropyrimidines (capecitabine, 5-FU) is standard of care at most major cancer centers. TPMT and NUDT15 testing before thiopurines (mercaptopurine, thioguanine) is similarly well-established. UGT1A1 guides irinotecan and nilotinib dosing.

Key genes in this class

Medications in this class with pharmacogenetic guidelines

Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.

Brand products in the Chemotherapy class

Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.

Which chemotherapy is right for your genetics?

This page covers the pharmacogenetics of chemotherapy agents in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.

Get your report Look up a medication

Informational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.

Get Your Report Now
Ready in One Minute